Skip to main content
. 2019 May 15;39(5):BSR20190379. doi: 10.1042/BSR20190379

Figure 4. The survival rate among different groups studied in established toxoplasmosis.

Figure 4

(GI) Uninfected; (GII) Infected untreated; (GIII) Infected preventive dose with sulphadiazine; (GIV) Infected preventive dose with nanoparticles green synthesized with palm seeds and nabka treated; (GV) Infected treated with sulphadiazine; (GVI) Infected treated with nanoparticles green synthesized with palm seeds and nabka treated.